Streamlining Medicare Skyrizi Prior Authorization

Navigating Medicare Skyrizi prior authorization for risankizumab across its indications requires precise understanding of payer-specific requirements. Klivira automates the submission process, reducing administrative burden.

For revenue cycle leaders and prior authorization coordinators, managing prior authorizations for high-cost specialty drugs like Skyrizi under Medicare presents unique challenges. This page outlines the specific considerations for risankizumab (Skyrizi) within the complex Medicare landscape, covering both Original Medicare and Part D plans.

Understanding Skyrizi (Risankizumab) Indications and Mechanism

Skyrizi, or risankizumab, is an IL-23 inhibitor developed by AbbVie. It is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe Crohn's disease. As a specialty medication, its high cost and specific usage criteria necessitate thorough prior authorization processes across all payer types, including Medicare.

Medicare Prior Authorization for Specialty Medications Like Skyrizi

The scope of prior authorization under Original Medicare (Parts A and B) is generally limited compared to commercial plans or Medicare Advantage (MA) plans. For services where Traditional Medicare requires prior authorization, submissions route through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. MACs such as Noridian, NGS, WPS, Palmetto, FCSO, and Novitas manage these processes. Medicare Advantage plans, operated by private insurers, typically have more extensive prior authorization requirements, often mirroring commercial plan structures.

Skyrizi Coverage Under Medicare Part D

As a prescription drug, Skyrizi falls under Medicare Part D, which is administered by commercial insurers as private contractors. These Part D plans establish their own formularies, which dictate coverage, formulary tiers, step-therapy protocols, and quantity limits for medications like risankizumab. Prior authorization for Part D drugs is managed by the individual Part D plan's Pharmacy Benefit Manager (PBM) per CMS-approved guidelines.

Navigating National and Local Coverage Determinations (NCDs/LCDs)

For services covered under Original Medicare, medical necessity for Skyrizi (if administered in a Part B setting, e.g., infusion) is guided by National Coverage Determinations (NCDs) published by CMS and Local Coverage Determinations (LCDs) published by the responsible MAC for each jurisdiction. These policies outline specific criteria that must be met for coverage. Accurate citations referencing the specific NCD number or LCD ID, MAC jurisdiction, and effective date are critical for successful prior authorization submissions.

Klivira's Approach to Medicare Skyrizi Prior Authorization

Klivira streamlines the prior authorization workflow for Skyrizi across the complex Medicare landscape. For Traditional Medicare, where prior authorization applies (e.g., specific Part B services), Klivira's MAC-aware routing handles per-jurisdiction submission specifics, leveraging NCD/LCD-aware policy logic. For Medicare Part D, Klivira connects with various PBMs and payer portals to automate submissions based on plan-specific formularies and step-therapy requirements.

Key Considerations for Medicare Skyrizi PA

**Documentation Accuracy:** Ensure all clinical documentation substantiates medical necessity per NCD/LCD criteria.
**MAC-Specific Requirements:** Adhere to the unique submission channels and forms mandated by the relevant Medicare Administrative Contractor.
**Part D Formulary Adherence:** Verify Skyrizi's formulary status, tier, and any step-therapy or quantity limits for the patient's specific Part D plan.
**Medical Necessity Justification:** Clearly articulate how the patient meets the established criteria for risankizumab's indicated conditions.
**Timely Submissions:** Be aware of specific turnaround timeframes for Medicare PA programs to avoid delays in patient care.

Frequently asked questions

Is Skyrizi prior authorization required for all Medicare patients?

Prior authorization requirements for Skyrizi vary based on the type of Medicare coverage. Original Medicare has limited PA scope for medical services, but Part D plans (for the drug itself) almost universally require PA. Medicare Advantage plans typically have broader PA requirements.

How do Medicare Administrative Contractors (MACs) impact Skyrizi PA?

MACs like Noridian and Novitas are responsible for processing claims and prior authorizations for Original Medicare within their jurisdictions. They publish Local Coverage Determinations (LCDs) that define medical necessity criteria for Part B services, which are crucial for justifying Skyrizi if administered in a Part B setting.

What role do National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) play for Skyrizi?

NCDs and LCDs are critical policy documents that establish the medical necessity criteria for services covered under Original Medicare. For Skyrizi, these determinations dictate whether the drug's use for specific indications (e.g., psoriatic arthritis) meets Medicare's coverage rules, particularly when administered in a Part B setting.

Can Klivira assist with Skyrizi prior authorizations for both Original Medicare and Medicare Part D plans?

Yes, Klivira is designed to streamline prior authorizations across the entire Medicare landscape. We provide MAC-aware routing for Traditional Medicare submissions where PA applies, and integrate with various PBMs and payer portals to manage Part D pharmacy prior authorizations for drugs like Skyrizi.

What are common reasons for Skyrizi prior authorization denials under Medicare?

Common denial reasons for Skyrizi under Medicare include insufficient documentation of medical necessity, failure to meet NCD or LCD criteria, lack of adherence to Part D plan step-therapy requirements, or incomplete submission of required clinical information. Appeals processes typically require submitting additional clinical data to substantiate the request.